AKT1 and acute lymphoblastic leukemia: Previous studies reported that Akt drives glucocorticoid resistance in acute lymphoblastic leukemia.13 These results suggest that CIP2A may contribute to Dex resistance through the inhibition of CIP2A-Akt activation.